PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa

(2013) Manujendra N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

(2013) D Chiron et al.   Blood Cancer Journal

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

(2012) Z. Y. Xu-Monette et al.   BLOOD

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells

(2012) David Chiron et al.   BLOOD CELLS MOLECULES AND DISEASES

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction

(2012) G Descamps et al.   BRITISH JOURNAL OF CANCER

Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells

(2012) S. Surget et al.   CANCER RESEARCH

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury

(2012) Masakazu Kakuni et al.   TOXICOLOGY LETTERS

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

(2011) N. C. Munshi et al.   BLOOD

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

(2011) David Chiron et al.   BRITISH JOURNAL OF HAEMATOLOGY

Resuscitating Wild-Type p53 Expression by Disrupting Ceramide Glycosylation: A Novel Approach to Target Mutant p53 Tumors

(2011) Y.-Y. Liu   CANCER RESEARCH

An inverse docking approach for identifying new potential anti-cancer targets

(2011) Sam Z. Grinter et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

(2010) Dina Ali et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

(2010) L. Lode et al.   HAEMATOLOGICA

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Therapeutic targeting of p53 by small molecules

(2010) Galina Selivanova   SEMINARS IN CANCER BIOLOGY

Reactivation of p53: from peptides to small molecules

(2010) Christopher J. Brown et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

p53-based Cancer Therapy

(2010) D. P. Lane et al.   Cold Spring Harbor Perspectives in Biology

DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance

(2009) Carmen Stanganelli et al.   ANNALS OF HEMATOLOGY

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

(2008) G Schilling et al.   LEUKEMIA